Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus

F. Martini, A. Farsi, A. M. Gori, M. Boddi, S. Fedi, M. P. Domeneghetti, A. Passaleva, D. Prisco, R. Abbate

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet. Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasminogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p <0.01) and to controls (p <0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.

Original languageEnglish
Pages (from-to)206-211
Number of pages6
JournalLupus
Volume5
Issue number3
Publication statusPublished - 1996

Fingerprint

Antiphospholipid Antibodies
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Systemic Lupus Erythematosus
Plasminogen Activator Inhibitor 2
Passive Cutaneous Anaphylaxis
Thromboplastin
leukocyte procoagulant activity
Monocytes
Healthy Volunteers
Thrombosis
Serum

Keywords

  • Antiphospholipid antibodies
  • Monocyte
  • Procoagulant activity
  • SLE

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Martini, F., Farsi, A., Gori, A. M., Boddi, M., Fedi, S., Domeneghetti, M. P., ... Abbate, R. (1996). Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus, 5(3), 206-211.

Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. / Martini, F.; Farsi, A.; Gori, A. M.; Boddi, M.; Fedi, S.; Domeneghetti, M. P.; Passaleva, A.; Prisco, D.; Abbate, R.

In: Lupus, Vol. 5, No. 3, 1996, p. 206-211.

Research output: Contribution to journalArticle

Martini, F, Farsi, A, Gori, AM, Boddi, M, Fedi, S, Domeneghetti, MP, Passaleva, A, Prisco, D & Abbate, R 1996, 'Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus', Lupus, vol. 5, no. 3, pp. 206-211.
Martini, F. ; Farsi, A. ; Gori, A. M. ; Boddi, M. ; Fedi, S. ; Domeneghetti, M. P. ; Passaleva, A. ; Prisco, D. ; Abbate, R. / Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. In: Lupus. 1996 ; Vol. 5, No. 3. pp. 206-211.
@article{41593b3f5c2b4955a53441fe22c5bb6a,
title = "Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus",
abstract = "Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet. Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasminogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p <0.01) and to controls (p <0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.",
keywords = "Antiphospholipid antibodies, Monocyte, Procoagulant activity, SLE",
author = "F. Martini and A. Farsi and Gori, {A. M.} and M. Boddi and S. Fedi and Domeneghetti, {M. P.} and A. Passaleva and D. Prisco and R. Abbate",
year = "1996",
language = "English",
volume = "5",
pages = "206--211",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus

AU - Martini, F.

AU - Farsi, A.

AU - Gori, A. M.

AU - Boddi, M.

AU - Fedi, S.

AU - Domeneghetti, M. P.

AU - Passaleva, A.

AU - Prisco, D.

AU - Abbate, R.

PY - 1996

Y1 - 1996

N2 - Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet. Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasminogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p <0.01) and to controls (p <0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.

AB - Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet. Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasminogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p <0.01) and to controls (p <0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.

KW - Antiphospholipid antibodies

KW - Monocyte

KW - Procoagulant activity

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=0029949753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029949753&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 206

EP - 211

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 3

ER -